Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LEVETIRACETAM

All products: Limited Use (codes 473)

Other products in the same Health Canada class (N03AX) — coverage varies; not interchangeable

  • Lamotrigine (Lamictal): general benefit
  • Topiramate (Topamax Sprinkle): general benefit, Limited Use 321, Not a benefit
  • Brivaracetam (Brivlera): limited Use 548
  • Cenobamate (Xcopri): limited Use 719
  • Lacosamide (Vimpat): limited Use 430
  • Perampanel (Fycompa): limited Use 430, 564

14 more in the class list below

Keppra · DIN 02247029 · 750mg · tablet

Limited Use — Reason for Use code 473 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 473 required
Write on scriptLU code 473 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 473
Reason for Use code 473 As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Keppra · DIN 02247029 Manufacturer: UCB Canada Inc.; listing date 2007-11-10 Health Canada: Marketed since 2011-06-02 · brand KEPPRA · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 750 MG · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.5416 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71264 · Verify on the e-Formulary ↗ (DIN 02247029)

Source record
DIN 02247029: Keppra Raw flags: sec12=Y, sec3=Y Item: 281200093; group id 434; item number 1085; lccId 00266; manufacturer id UCB Source form: Tab; strength: 750mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.0089; ministry $0.5416 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247029 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71264
Interchangeable products
Ach-Levetiracetam · DIN 02399792 · $0.5416 Act Levetiracetam · DIN 02274205 · $0.5416 Apo-Levetiracetam · DIN 02285940 · $0.5416 Auro-Levetiracetam · DIN 02375265 · $0.5416 Jamp Levetiracetam Tablets · DIN 02504588 · $0.5416 Jamp-Levetiracetam · DIN 02403048 · $0.5416 Levetiracetam · DIN 02353369 · $0.5416 Levetiracetam · DIN 02442566 · $0.5416 M-Levetiracetam · DIN 02524589 · $0.5416 Mint-Levetiracetam · DIN 02442418 · $0.5416 NRA-Levetiracetam · DIN 02499215 · $0.5416 PMS-Levetiracetam · DIN 02296136 · $0.5416 Riva-Levetiracetam · DIN 02482290 · $0.5416 Sandoz Levetiracetam · DIN 02462001 · $0.5416
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit)

LACOSAMIDE

· 44 products · Limited Use, codes 430 · strengths: 50mg, 100mg, 150mg, 200mg · Tab

PERAMPANEL

· 12 products · Limited Use, codes 430, 564 · strengths: 2mg, 4mg, 6mg, 8mg, 10mg, 12mg · Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS KEPPRA (levetiracetam) is indicated as adjunctive therapy in the management of adult (> 18 years of age) patients with epilepsy who are not satisfactorily controlled by conventional therapy. 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of KEPPRA in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics and 10.3 Pharmacokinetics, Special Populations and Conditions, Pediatrics). 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or efficacy (see 7.1.4 Geriatrics, 4.2 Recommended Dose and Dosage Adjustment, Geriatrics and 10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics). https://pdf.hres.ca/dpd_pm/00069867.PDF PM date: January 21, 2003 Source product: KEPPRA; DIN 02247027; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.